Efficacy of delafloxacin against the biothreat pathogen Bacillus anthracis.

Sandra McCurdyStephanie A HalasohorisAshley L BabyakSanae LembirikRandall HooverMark HickmanJennifer ScarffChristopher P KlimkoChristopher K CoteJ Matthew Meinig

Published in: The Journal of antimicrobial chemotherapy (2023)

Given the high bar set by the 100 × LD50 challenge dose in this study, the results from delafloxacin treatment are promising for the treatment of inhaled anthrax.

Keyphrases

cystic fibrosis
combination therapy
replacement therapy